AndrewBlauveltMDMBA

PubMed

• Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinica...
  Alvaro González-Cantero, Guilherme Muzy, William N Malatestinic, Anastasia Lampropoulou, Sophia Kyoungah See, Can Mert, April Armstrong, Saakshi Khattri, Meghan Feely,...> ;Dermatology and Therapy. 2024 Mar 23
• Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
  Bruce Strober, Andrew Blauvelt, Richard B Warren, Kim A Papp, April W Armstrong, Kenneth B Gordon, Akimichi Morita, Andrew F Alexis, Mark Lebwohl, Peter Foley, Renata ...> ;Journal of the European Academy of Dermatology and Venereology. 2024 Mar 7
• Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials.
  Andrew Blauvelt, April Armstrong, Joseph F Merola, Bruce Strober, Dirk de Cuyper, Luke Peterson, Owen Davies, Jeffrey L Stark, Mark Lebwohl> ;Journal of the American Academy of Dermatology. 2024 Mar 4
• Reanalysis Following Removal of Participants From 1 Site in Multicenter Trial of Upadacitinib vs Dupilumab for Atopic Dermatitis.
  Andrew Blauvelt> ;JAMA Dermatology. 2024 Mar 1
• Rapid resolution of guttate psoriasis without recurrence for one year following two doses of guselkumab.
  Carlota Abbad-Jaime de Aragón, Emilio Berna-Rico, Pedro Jaén, Andrew Blauvelt, Álvaro González-Cantero> ;International Journal of Dermatology. 2024 Apr 1
• 1 citations
  Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial.
  Blauvelt, A., Draelos, Z., Stein Gold, L., Alonso-Llamazares, J., Bhatia, N., DuBois, J., Forman, S., Gooderham, M., Green, L., Guenthner, S., Hebert, A., Lain, E., Mo...> ;Journal of the American Academy of Dermatology. 2024 Jan 20
• Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase 3 poetyk trials.
  Warren, R., Imafuku, S., Paul, C., Szepietowski, J., Spelman, L., Passeron, T., Vritzali, E., Napoli, A., Kisa, R., Buck, A., Banerjee, S., Thaçi, D., Lebwohl, M., Sof...> ;The British Journal of Dermatology. 2024 Jan 16
• 1 citations
  Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.
  Andrew Blauvelt, Phoebe Rich, Howard Sofen, Bruce Strober, Joseph F Merola, Mark Lebwohl, Akimichi Morita, Jacek C Szepietowski, Jo Lambert, Lauren Hippeli, Elizabeth ...> ;Journal of the American Academy of Dermatology. 2024 Apr 1
• Correction to: Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Derm...
  Jonathan I Silverberg, April Armstrong, Andrew Blauvelt, Kristian Reich> ;American Journal of Clinical Dermatology. 2024 Jan 1
• The Best Psoriasis Medications Emerge.
  Andrew Blauvelt, Megan H Noe> ;JAMA Dermatology. 2024 Jan 1
• 2 citations
  Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS).
  Richard B Warren, Lars E French, Andrew Blauvelt, Richard G Langley, Alexander Egeberg, Ulrich Mrowietz, Hamish J A Hunter, Melinda Gooderham, Per Soerensen, Philippe ...> ;Journal of the American Academy of Dermatology. 2024 Mar 1
• 1 citations
  Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review.
  Andrew Blauvelt, Richard G Langley, Kenneth B Gordon, Jonathan I Silverberg, Kilian Eyerich, Morten O A Sommer, Jakob Felding, Richard B Warren> ;Dermatology and Therapy. 2023 Dec 1
• Tildrakizumab-induction therapy followed by as-needed dosing in patients with mild-to-moderate psoriasis.
  Emilio Berna-Rico, Almudena Goas, Javier Pérez-Bootello, María Asunción Ballester-Martinez, Pedro Jaén, Andrew Blauvelt, Álvaro González-Cantero, Abbad-Jaime de Aragón...> ;Clinical and Experimental Dermatology. 2024 Feb 14
• Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascend...
  Karen A Veverka, Steven T G Thng, Jonathan I Silverberg, April W Armstrong, Josemund Menezes, Alexandre Kaoukhov, Andrew Blauvelt> ;Journal of the American Academy of Dermatology. 2024 Mar 1
• Increased risk of severe generalized pustular psoriasis due to tuberculosis screening delay for spesolimab initiation.
  Madison Hackley, Daphne Thampy, Shayan Waseh, Steven R Feldman, Andrew Blauvelt, Jeffrey M Weinberg, Sergio Schwartzman, Wilson Liao, Ronald Prussick, Jeffrey M Cohen,...> ;Journal of the American Academy of Dermatology. 2024 Feb 1
• Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1.
  Eric L Simpson, Andrew Blauvelt, Jonathan I Silverberg, Michael J Cork, Norito Katoh, Thomas Mark, Shannon K R Schneider, Andreas Wollenberg> ;American Journal of Clinical Dermatology. 2024 Jan 1
• Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.
  Andrew Blauvelt, Alyssa Garrelts, William Malatestinic, Julie Birt, Baojin Zhu, Meghan Feely> ;Dermatology and Therapy. 2023 Nov 1
• 1 citations
  Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combi...
  Jonathan I Silverberg, April Armstrong, Andrew Blauvelt, Kristian Reich> ;American Journal of Clinical Dermatology. 2023 Nov 1
• Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials.
  Eric L Simpson, Andrew E Pink, Andrew Blauvelt, Melinda Gooderham, April W Armstrong, Margitta Worm, Norito Katoh, Ketty Peris, Luis Puig, Sébastien Barbarot, Thomas M...> ;American Journal of Clinical Dermatology. 2023 Nov 1
• 1 citations
  Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial u...
  Kim A Papp, Andrew Blauvelt, Lluís Puig, Mamitaro Ohtsuki, Stefan Beissert, Melinda Gooderham, Ahmad Z Amin, Jie Liu, Tianshuang Wu, Tofial Azam, Vassilis Stakias, Ram...> ;Journal of the American Academy of Dermatology. 2023 Dec 1
• 5 citations
  Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label exte...
  Andrew Blauvelt, Barry Ladizinski, Vimal H Prajapati, Vivian Laquer, Alison Fischer, Samantha Eisman, Xiaofei Hu, Tianshuang Wu, Brian M Calimlim, Blair Kaplan, Yingyi...> ;Journal of the American Academy of Dermatology. 2023 Sep 1
• 6 citations
  Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIA...
  Bruce Strober, Carle Paul, Andrew Blauvelt, Diamant Thaçi, Luis Puig, Mark Lebwohl, Katy White, Veerle Vanvoorden, Delphine Deherder, Natalie Nunez Gomez, Kilian Eyerich> ;Journal of the American Academy of Dermatology. 2023 Sep 1
• 8 citations
  Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial.
  Amy S Paller, Carsten Flohr, Michael Cork, Anthony Bewley, Andrew Blauvelt, H Chih-Ho Hong, Shinichi Imafuku, Marie L A Schuttelaar, Eric L Simpson, Weily Soong, Petra...> ;JAMA Dermatology. 2023 Jun 1
• 4 citations
  Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials.
  Andrew Blauvelt, Mark Lebwohl, Richard G Langley, Katelyn Rowland, Ya-Wen Yang, Daphne Chan, Megan Miller, Yin You, Jenny Yu, Diamant Thaҫi, Peter Foley, Kim A Papp> ;Journal of the American Academy of Dermatology. 2023 Aug 1
• 15 citations
  Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
  Andrew Blauvelt, Jacob P Thyssen, Emma Guttman-Yassky, Thomas Bieber, Esther Serra-Baldrich, Eric Simpson, David Rosmarin, Hany Elmaraghy, Eric Meskimen, Chitra R Nata...> ;The British Journal of Dermatology. 2023 May 24
• Join now to see all

Journal Articles

• Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis  
  Andrew Blauvelt, Steven Kempers, Stephen Tyring, Glynis Ablon, The New England Journal of Medicine
• Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients with Moderate to Severe Plaque Psoriasis  
  Andrew Blauvelt, Craig L Leonardi, Jashin J Wu, JAMA Dermatology
• Certolizumab Pegol for the Treatment of Patients with Moderate‐to‐Severe Chronic Plaque Psoriasis: Pooled Analysis of Week 16 Data from 3 Randomized Controlled Trials  
  Andrew Blauvelt, MD, Journal of The European Academy of Dermatology and Venereology
• Efficacy of Guselkumab Compared with Adalimumab and Placebo for Psoriasis in Specific Body Regions  
  Bruce Randazzo, Andrew Blauvelt, JAMA
• A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis  
  Gordon KB, Leonardi CL, Lebwohl M, Blauvelt A, Cameron GS, Braun D, Erickson J, Heffernan M, J Am Acad Dermatol, 9/19/2014
• Secukinumab administration by pre-filled syringe: efficacy, safety, and usability results from a randomized controlled trial in psoriasis (FEATURE)  
  Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, Singh V, Pathan R, Papavassilis C, Cooper S, Br J Dermatol, 8/16/2014
• A novel, short, and simple screening questionnaire can suggest presence of psoriatic arthritis in psoriasis patients in a dermatology clinic  
  Garg N, Truong B, Ku JH, Devere TS, Ehst BD, Blauvelt A, Deodhar AA, Clin Rheumatol, 5/15/2014
• From the Medical Board of the National Psoriasis Foundation: the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current thera...  
  Hugh J, Van Voorhees AS, Nijhawan RI, Bagel J, Lebwohl M, Blauvelt A, Hsu S, Weinberg JM, J Am Acad Dermatol, 1/1/2014
• Secukinumab in plaque psoriasis--results of two phase 3 trials  
  Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele..., N Engl J Med, 1/1/2014
•  
  Varley CD, Deodhar AA, Ehst BD, Bakke A, Blauvelt A, Vega R, Yamashita S, Winthrop KL, Rheumatology (Oxford), 1/1/2014
• Antimicrobial peptide LL-37 produced by HSV-2-infected keratinocytes enhances HIV infection of Langerhans cells  
  Ogawa Y, Kawamura T, Matsuzawa T, Aoki R, Gee P, Yamashita A, Moriishi K, Yamasaki K, Koyanagi Y, Blauvelt A, Shimada S, Cell Host Microbe, 1/1/2013
• Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to eta...  
  Kalb RE, Blauvelt A, Sofen HL, Chevrier M, Amato D, Calabro S, Wang J, Schenkel B, Gottlieb AB, J Drugs Dermatol, 1/1/2013
• Oral administration of the CCR5 inhibitor, maraviroc, blocks HIV ex vivo infection of Langerhans cells within the epithelium  
  Matsuzawa T, Kawamura T, Ogawa Y, Takahashi M, Aoki R, Moriishi K, Koyanagi Y, Gatanaga H, Blauvelt A, Shimada S, J Invest Dermatol, 1/1/2013
• Delayed wound healing due to increased interleukin-10 expression in mice with lymphatic dysfunction  
  Kimura T, Sugaya M, Blauvelt A, Okochi H, Sato S, J Leuk Biol, 1/1/2013
• Implications for biologic therapy: Staphylococcus aureus decolonization of individuals with a history of recurrent skin and soft-tissue infections  
  Ku JH, Winthrop KL, Varley CD, Sullivan A, Ehst BD, Blauvelt A, Deodhar AA, JAMA Dermatol, 1/1/2013
• Fatal ALK-negative systemic anaplastic large cell lymphoma presenting with disseminated cutaneous domeshaped papules and nodules  
  Bird JE, Leitenberger JJ, Solomon A, Blauvelt A, Hopkins S, Dermatol Online J, 1/1/2012
• The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label...  
  Gottlieb AB, Kalb RE, Blauvelt A, Heffernan MP, Sofen HL, Ferris LK, Kerdel FA, Calabro S, Wang J, Kerkmann U, Chevrier M, J Am Acad Dermatol, 1/1/2012
• Kaposi's sarcoma and human dermal microvascular endothelial cells infected with Kaposi’s sarcoma-associated herpesvirus express CCL21  
  Sugaya M, Reed S, Rose PP, de la Motte S, Raggo CM, Kurtz SE, Moses AV, Früh K, Blauvelt A, J Dermatol Sci, 1/1/2011
• Treatment of psoriasis in the setting of excessive alcohol intake: from the Medical Board of the National Psoriasis Foundation  
  Pugliese DJ, Gottlieb AB, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF Jr, Blauvelt A, Van Voorhees AS, Psoriasis Forum, 1/1/2011
• Sequelae of World War II: an outbreak of chronic cutaneous nontuberculous mycobacterial infections among Satowanese islanders  
  Lillis JV, Ansdell VE, Ruben K, Simpson EL, Tumbaga G, Ansdell D, Bremmer S, Kurtz SE, White CR, Blauvelt A, Winthrop KL, Clin Infect Dis, 1/1/2009
•  
  Fitch EL, Rizzo HL, Kurtz SE, Wegmann KW, Gao W, Benson JM, Hinrichs DJ, Blauvelt A, J Invest Dermatol, 1/1/2009
• Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo...  
  Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators, Lancet, 1/1/2008
• New concepts in the pathogenesis and treatment of psoriasis: key roles for IL-23, IL-17A and TGF-1  
  Blauvelt A, Expert Rev Dermatol, 1/1/2007
• Handbook of Pediatric HIV Care  
  Blauvelt A, 1/1/2006
• The role of Langerhans cells in sexual transmission of HIV-1  
  Kawamura T, Kurtz SE, Blauvelt A, Shimada S, J Dermatol Sci, 1/1/2005
• Join now to see all

Books/Book Chapters

• Moderate to Severe Psoriasis 
  Chapter: Ustekinumab. 
  Page 217 - 230Blauvelt AEditors: Levin E, Leon A, Wu JJ, Gottlieb AB, Koo JYM.CRC Press, Boca Raton, FLEdition 4th,2014
• Moderate-to-Severe Psoriasis 
  Chapter: Ustekinumab and ABT-874. 
  Page 347 - 364Blauvelt AEditors: Koo JYM, Lee CS, Lebwohl MG, Weinstein GD, Gottlieb A.Informa Healthcare, New York, NYEdition 3rd,2009
• Fitzpatrick's Dermatology in General Medicine 
  Chapter: Skin Disease in Acute and Chronic Immunosuppression. 
  Page 267 - 278Kauls L, Blauvelt AEditors: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ.The McGraw-Hill Companies, Inc., New York, NYEdition 7th,2008
• Clinical and Basic Immunodermatology. 
  Chapter: HIV Disease and AIDS. 
  Page 323 - 334Blauvelt AEditors: Gaspari AA, Tyring SK.Springer, London2008
• Fitzpatrick's Dermatology in General Medicine 
  Chapter: Pityriasis Rosea. 
  Page 362 - 366Blauvelt AEditors: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ.The McGraw-Hill Companies, Inc., New York, NYEdition 7th,2008
• Textbook of Pediatric HIV Care. 
  Chapter: Cutaneous Diseases. 
  Page 413 - 430Blauvelt AEditors: Zeichner SL, Read JS.Cambridge University Press, Cambridge, MA2005
• Lectureship Series in Dermatology 
  Chapter: Kaposi’s sarcoma-associated herpesvirus. 
  Blauvelt AYale University/ Fujisawa Healthcare, Inc.2004
• Fitzpatrick's Dermatology in General Medicine 
  Chapter: Mucocutaneous Manifestations of the Non-HIV-Infected Immunosuppressed Host. 
  Page 1152 - 1164Blauvelt AEditors: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI.McGraw-Hill, Inc., New York, NYEdition 6th,2003
• Handbook of Pediatric HIV Care 
  Chapter: Cutaneous Diseases. 
  Page 321 - 335Blauvelt AEditors: Zeichner SL, Read JS.Lippincott Williams & Wilkens, Philadelphia, PAEdition 1st,1999
• Encyclopedia of Immunology 
  Chapter: Langerhans Cells. 
  Page 1528 - 1532Blauvelt AEditors: Delves PJ, Roitt IM.Academic Press Ltd., LondonEdition 2nd,1998
• Join now to see all

Abstracts/Posters

• Evaluation of infections with secukinumab in a pooled analysis of 10 clinical studies of moderate-to-severe plaque psoriasis (poster).
  Blauvelt A, 44th Annual European Society for Dermatological Research Meeting, Copenhagen, Denmark, 9/1/2014
• Candidiasis in secukinumab-treated subjects is non-serious and transient: a pooled analysis of data from 10 phase 2 and 3 clinical trials in psoriasis (poster).
  Blauvelt A, Federation of Clinical Immunology Societies Annual Meeting, Chicago, IL, 6/1/2014
• Secukinumab efficacy and safety: results from the first study of secukinumab in prefilled syringes in subjects with chronic plaque-type psoriasis response at 12 weeks ...
  Blauvelt A, Dermatology Nurses’ Association Annual Meeting, Orlando, FL, 5/1/2014
• Secukinumab efficacy and safety: results from the first study of secukinumab in prefilled syringes in subjects with chronic plaque-type psoriasis response at 12 weeks ...
  Blauvelt A, American Academy of Dermatology Annual Meeting, Denver, CO, 3/1/2014
• Secukinumab shows substantial improvement in both psoriasis symptoms and physical functioning in moderate-to-severe plaque psoriasis subjects with psoriatic arthritis:...
  Blauvelt A, American College of Rheumatology Annual Meeting, San Diego, CA, 10/1/2013
• Secukinumab shows substantial improvement in both psoriasis symptoms and physical functioning in moderate-to-severe plaque psoriasis subjects with psoriatic arthritis:...
  Blauvelt A, European Academy of Dermatology and Venereology Annual Meeting, Istanbul, Turkey, 10/1/2013
• Ixekizumab rapidly improves psoriasis within 2 weeks (poster).
  Blauvelt A, Maui Derm: Advances in Cosmetic & Medical Dermatology, Wailea, HI, 1/1/2013
• Simple questions in the dermatology office may reasonably exclude, but do not reliably identify psoriatic arthritis patients: results from the Center of Excellence for...
  Blauvelt A, American College of Rheumatology Annual Meeting, Washington, DC, 11/1/2012
• Simple questions in the dermatology office may reasonably exclude, but do not reliably identify psoriatic arthritis patients: results from the Center of Excellence for...
  Blauvelt A, 3rd World Psoriasis and Psoriatic Arthritis Conference, Stockholm, Sweden, 6/1/2012
• Delayed wound healing due to increased interleukin-10 expression in mice with lymphatic dysfunction (poster).
  Blauvelt A, Society for Investigative Dermatology Annual Meeting, Raleigh, NC, 5/1/2012
• Do we know the cost of dermatologic specialty care? A survey of dermatology providers, residents and patients (poster).
  Blauvelt A, Society for Investigative Dermatology Annual Meeting, Raleigh, NC, 5/1/2012
• Higher prevalence of Staphylococcal aureus colonization in psoriatic patients may predispose to incident infections (poster).
  Blauvelt A, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Annual Meeting, Naples, Italy, 7/1/2011
• An orally delivered CCR5 inhibitor, Maraviroc, prevents HIV-1 acquisition in Langerhans cells and transmission to CD4+ T cells (poster).
  Blauvelt A, Society for Investigative Dermatology Annual Meeting, Phoenix, AZ, 5/1/2011
• High prevalence of psoriatic arthritis with a significant impact on quality of life in psoriasis patients evaluated at a multidisciplinary center for complex psoriatic...
  Blauvelt A, Society for Investigative Dermatology Annual Meeting, Phoenix, AZ, 5/1/2011
• Staphylococcus aureus colonization does not increase the rate of infection among psoriasis patients using biologic therapy (poster).
  Blauvelt A, Society for Investigative Dermatology Annual Meeting, Phoenix, AZ, 5/1/2011
• ESPRIT: Interim results from a 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis (poster).
  Blauvelt A, American Academy of Dermatology Annual Meeting, New Orleans, LA, 2/1/2011
• Colonization and infection by Staphylococcus aureus among those using biologic therapy (poster).
  Blauvelt A, American College of Rheumatology Annual Meeting, Atlanta, GA, 10/1/2010
• Infliximab improves high-impact features of psoriasis in patients with an inadequate response to etanercept: analysis of PSUNRISE results (poster).
  Blauvelt A, European Academy of Dermatology and Venereology Annual Meeting, Gothenburg, Sweden, 10/1/2010
• Efficacy, safety, and health-related quality of life of infliximab therapy in plaque psoriasis patients previously treated with etanercept: analysis of PSUNRISE study ...
  Blauvelt A, Congress of the Psoriasis International Network, Paris, France, 7/1/2010
• IL-23 and Th17 cytokines control cutaneous infection with Candida albicans as well as C. albicans-induced epidermal hyperplasia (poster).
  Blauvelt A, Society for Investigative Dermatology Annual Meeting, Atlanta, GA, 5/1/2010
• IL-23-mediated epidermal hyperplasia is dependent on IL-17A in mice (poster).
  Blauvelt A, Society for Investigative Dermatology Annual Meeting, Atlanta, GA, 5/1/2010
• Production of LL-37 during herpes simplex virus type 2 infection in human keratinocytes enhances HIV susceptibility in Langerhans cells (poster).
  Blauvelt A, Society for Investigative Dermatology Annual Meeting, Atlanta, GA, 5/1/2010
• Infliximab therapy in psoriasis patients previously treated with etanercept: final efficacy and safety results from a multicenter, prospective study (poster).
  Blauvelt A, American Academy of Dermatology, Miami, FL, 3/1/2010
• Prevalence of Staphylococcus aureus colonization among those using biologic therapy (poster).
  Blauvelt A, American College of Rheumatology Annual Scientific Meeting, Philadelphia, PA, 10/1/2009
• Psoriasis as a systemic inflammatory disease: increases in circulating Th17, Th1, Th17/Th1, and Th22 cells (poster).
  Blauvelt A, 2nd World Psoriasis and Psoriatic Arthritis Conference, Stockholm, Sweden, 6/1/2009
• Join now to see all

Lectures

• Late-breaking Research: Clinical Trials 
  American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/2/2019
• Crossfire symposium: the advent of biosimilars (invited speaker). 
  Amsterdam, Netherlands - 10/1/2014
• JAK inhibitors as treatment in psoriasis: understanding efficacy (invited speaker). 
  Copenhagen, Denmark - 9/1/2014
• Ustekinumab therapy for psoriasis (invited speaker). 
  Vancouver, Canada - 8/1/2014
• Update on co-morbidities and biologic treatment options for psoriasis. 
  University of California, Irvine, CA - 7/1/2014
• Immunology 101: HIV and the skin (invited speaker). 
  Park City, UT - 6/1/2014
• Immunology 101: psoriasis, atopic dermatitis, and melanoma immunology (invited speaker). 
  Park City, UT - 6/1/2014
• Immunology 101: the basics (invited speaker). 
  Park City, UT - 6/1/2014
• Psoriasis case presentations (invited speaker). 
  Park City, UT - 6/1/2014
• The psoriasis pipeline (invited speaker). 
  Park City, UT - 6/1/2014
• Impact of ixekizumab on blood neutrophil levels and the incidence of infections caused by Candida albicans or Staphylococcus aureus (invited speaker). 
  Albuquerque, NM - 5/1/2014
• Psoriasis: general features and approach to the patient (invited speaker). 
  Barcelona, Spain - 5/1/2014
• Immunology of psoriasis (invited speaker). 
  Denver, CO - 3/1/2014
• Off-label use of biologics (invited speaker). 
  Denver, CO - 3/1/2014
• Off-label use of ustekinumab (invited speaker). 
  Denver, CO - 3/1/2014
• Secukinumab efficacy in subjects with moderate-to-severe plaque psoriasis and concomitant psoriatic arthritis: a subanalysis of the ERASURE study (invited speaker). 
  Denver, CO - 3/1/2014
• Cutaneous immunology: understanding the basis for targeted therapy in dermatology. 
  Oregon Health & Science University, Portland, OR - 3/1/2014
• HIV update for 2014 (invited speaker). 
  Wailea, HI - 1/1/2014
• Viruses. 
  Oregon Health & Science University, Portland, OR - 12/1/2013
• Biologics for psoriasis. 
  Oregon Health & Science University, Portland, OR - 10/1/2013
• Psoriasis in the 21st century: more than a skin disease and more you can do it about it. 
  Portland, OR - 10/1/2013
• 21st century management of psoriasis. 
  Sun Valley, ID - 9/1/2013
• Management of complex medical dermatology cases. 
  Sun Valley, ID - 9/1/2013
• Management of complex cases of psoriasis. 
  Sunriver, OR - 8/1/2013
• Off-label uses of biologics. 
  Sunriver, OR - 8/1/2013
• Join now to see all

Other

• The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis 
  Andrew Blauvelt, MD, Clinical Reviews in Allergy & Immunology
  https://www.doximity.com/articles/8a215fc2-3fa4-4034-912b-b50de86c932a
  UpToDate, Wolters Kluwer Health - 2012-05-09
• Pathophysiology of psoriasis. 
  Ehst BD, Blauvelt A, UpToDate (Online)
  1/1/2012